Davis, Biomarin Pharmaceutical EVP sells $1.6m in shares
#Biomarin Pharmaceutical #George Davis #Insider Trading #Stock Sale #NASDAQ:BMRN #Market Analysis #Pharmaceutical Stocks
📌 Key Takeaways
- George Eric Davis sold $1.6 million worth of Biomarin Pharmaceutical shares at $61.36 each
- Davis still owns 72,453 shares following the transaction
- Biomarin missed EPS expectations but exceeded revenue forecasts in Q4 2025
- Analysts have mixed views on the company's future prospects with varying price targets
📖 Full Retelling
George Eric Davis, Executive Vice President and Chief Legal Officer at Biomarin Pharmaceutical Inc (NASDAQ:BMRN), sold 26,061 shares of common stock on February 26, 2026, at $61.36 per share, totaling approximately $1.6 million in a routine insider trading transaction. The sale price was close to the stock's current trading level of $61.11, with the company carrying an $11.77 billion market cap. According to a Form 4 filing with the Securities and Exchange Commission, Davis also acquired shares of Biomarin Pharmaceutical common stock on February 25, 2026, totaling 15,224 shares across three separate transactions. Following the sale, Davis directly owns 72,453 shares of the company. Despite the insider sale, InvestingPro analysis suggests that Biomarin appears undervalued at current levels, with the platform's Fair Value indicating significant upside potential and the company maintaining a 'GREAT' financial health score. In other recent developments, BioMarin Pharmaceutical reported its fourth-quarter 2025 financial results, missing earnings per share forecasts with $0.46 compared to the anticipated $0.77, but exceeding revenue expectations at $875 million, surpassing forecasts by 5.51%. The company has also recently announced its acquisition of Amicus Therapeutics, which has drawn investor attention, while analysts have presented mixed outlooks on the company's future prospects.
🏷️ Themes
Insider Trading, Pharmaceutical Industry, Market Analysis
📚 Related People & Topics
Insider trading
Trading using nonpublic information
# Insider Trading **Insider trading** is the trading of a public company's stock or other securities (such as bonds or stock options) based on **material, nonpublic information** about the company. While the practice is common, its legality is subject to complex regulations that vary significantly ...
Entity Intersection Graph
Connections for Insider trading:
🌐
SEC filing
5 shared
👤
New York Stock Exchange
4 shared
👤
Rachel Haurwitz
3 shared
🌐
ZWS
2 shared
🌐
Biopharmaceutical
2 shared
Original Source
try{ var _=i o; . if(!_||_&&typeof _==="object"&&_.expiry Netflix declines to match Paramount Skydance bid for Warner Bros Dorsey’s Block slashes workforce 40% to embrace AI-native future, shares gain S&P 500, Nasdaq end in the red as Nvidia drags chip stocks lower Gold prices mixed as U.S.-Iran nuclear talks end after ’significant progress’ (South Africa Philippines Nigeria) Davis, Biomarin Pharmaceutical EVP sells $1.6m in shares By Investing.com Insider Trading Published 02/26/2026, 08:40 PM Davis, Biomarin Pharmaceutical EVP sells $1.6m in shares 0 BMRN -0.54% George Eric Davis, Executive Vice President and Chief Legal Officer at Biomarin Pharmaceutical Inc (NASDAQ:BMRN) , sold 26,061 shares of common stock on February 26, 2026, at a price of $61.36, totaling approximately $1.6 million. The sale price was close to the stock’s current trading level of $61.11, with the company carrying an $11.77 billion market cap. According to a Form 4 filing with the Securities and Exchange Commission, Davis also acquired shares of Biomarin Pharmaceutical common stock on February 25, 2026. These acquisitions include 6,177 shares, 6,675 shares and 2,372 shares. Following the sale, Davis directly owns 72,453 shares of the company. According to InvestingPro analysis, Biomarin appears undervalued at current levels, with the platform’s Fair Value suggesting significant upside potential. The company maintains a "GREAT" financial health score. Investors can access 9 additional InvestingPro Tips and comprehensive analysis for deeper insights. In other recent news, BioMarin Pharmaceutical Inc. reported its fourth-quarter 2025 financial results, where the company missed earnings per share forecasts but exceeded revenue expectations. The EPS came in at $0.46, which was below the anticipated $0.77, resulting in a 40.26% negative surprise. However, the company’s revenue reached $875 million, surpassing forecasts by 5.51%. In terms of mergers, BioMarin recently announced its acquisition of Am...
Read full article at source